Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Neuroectodermal Tumors, Primitive 2Neoplasms 2Uterine Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Hamartoma Syndrome, Multiple 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Angiomyolipoma 1Advanced Solid Tumor 1

Interventions

radium Ra 223 dichloride 1enzalutamide 1disitamab vedotin 1dactolisib 1VT-464 1NVP-BKM120 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Castration-resistant Prostate Cancer × dactolisib × Clear all
NCT01634061 2020-12-09

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Novartis

Phase 1 Completed
43 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡